Sir: Sexual dysfunction is a known integral component of depressive illnesses, and most antidepressant drugs have been associated with sexual dysfunction, especially those agents with increased serotonergic activity. [1] [2] [3] [4] In fact, the use of selective serotonin reuptake inhibitors (SSRIs) has been associated with significant ejaculatory dysfunction and orgasm-related difficulties.
1,4-6 However, the incidence of sexual dysfunction varies with SSRIs. The package inserts report a range from 2% (fluoxetine) up to 20% (sertraline, paroxetine), 5, 7 and in the clinical setting, sexual dysfunction has been reported to occur in 7.8% to 75% of depressed patients. [5] [6] [7] [8] These differences in reported incidences may be due to a number of factors including duration of study, patients' inhibitions about reporting sexual dysfunction, lack of inquiry on the part of the clinician, or differences in the parameters used to elicit sexual function information (i.e., rating scales). 1, 4, 5, 7 In the study with the highest incidence of sexual dysfunction, patients were routinely questioned about their sexual function. 8 Various strategies have been used to manage antidepressantinduced sexual dysfunction; these include drug holidays, lowering the dosage, switching agents, and adjunctive therapy. [5] [6] [7] 9 Spontaneous reductions in sexual side effects have been reported toward the end of a 6-to 8-week treatment period.
1,2 However, in the clinical setting, patients may not wait for spontaneous reductions and often discontinue their antidepressant therapy. Agents such as cyproheptadine, yohimbine, and amantadine have been reported to be helpful as adjunctive therapy. [10] [11] [12] Other strategies include switching to an antidepressant that does not carry this risk: bupropion, nefazodone, or mirtazapine. 1, 5, [13] [14] [15] Mirtazapine, a potent 5-HT 2 and 5-HT 3 antagonist along with α 2 -antagonistic properties, has been reported to have little or no incidence of sexual dysfunction. 3, 16 Since sexual side effects related to SSRI treatment are believed to be mediated through 5-HT 2 stimulation, possible relief of symptoms may result from blocking these receptors with mirtazapine. 16, 17 Reports that mirtazapine reverses sexual side effects of ongoing SSRI therapy led to the following case reports. [13] [14] [15] The following case series describes 4 patients who experienced sexual dysfunction while on SSRI therapy and consented to a trial of add-on, open-label mirtazapine therapy. Response to sexual functioning was either spontaneously reported (2 patients) or actively elicited (2 patients).
Case 1.
A 47-year-old woman with a past medical history of alcohol dependence and premenstrual syndrome responded to paroxetine, 20 mg/day, for panic attacks and generalized anxiety, yet lack of libido was noted by 8 weeks of therapy. She had previously discontinued treatment with fluoxetine, 40 mg/day, for 1 year because of sexual dysfunction. She reported sexual intercourse at least 2 times per week (baseline libido) prior to SSRI therapy. Mirtazapine, 15 mg at bedtime, was added, and at her next medication check 6 weeks later, she reported restoration of baseline sexual desire. Return of normal libido remains after 5 months of treatment with mirtazapine.
Case 2. A 30-year-old woman with a past medical history for chronic depression (> 3 years) had been treated with numerous antidepressants such as sertraline, venlafaxine, and bupropion with no response. However, this patient did respond to treatment with fluoxetine, 30 mg/day, but complained of loss of libido after 6 weeks of therapy. Mirtazapine, 15 mg at bedtime, was added, and libido returned to baseline within 2 months. This patient has sustained her normal libido for 3 months of mirtazapine treatment.
Case 3. A 36-year-old woman with a past medical history for posttraumatic stress disorder after a car accident responded well with paroxetine and zolpidem therapy. After 3 weeks of treatment with paroxetine, 30 mg/day, anorgasmia and decreased libido became prominent. Both of these symptoms improved within 1 week of initiating treatment with mirtazapine, 15 mg at bedtime. However, she discontinued this agent due to weight gain associated with increased appetite.
Case 4. A 49-year-old woman with depression reported "no sexual desire" after 2 months of paroxetine therapy. Her daily dose of paroxetine was 30 mg/day, and she was also taking clonazepam, 0.5 mg twice a day, for anxiety and insomnia. Mirtazapine, 15 mg/day, was added to her regimen at bedtime, and within a month she reported restoration of normal libido. Since then, her libido has been sustained for 2 months of mirtazapine treatment.
The cases reported herein demonstrate that mirtazapine may be beneficial in patients with SSRI-induced sexual dysfunction. These findings are consistent with the clinical pharmacology of mirtazapine, in that blockade of 5-HT 2 receptors may be related to lack of sexual side effects. All 4 patients reported resolution of their sexual side effects, which included anorgasmia and lack of libido, shortly after mirtazapine was added to their regimens. Criticisms of these cases may be that not all patients were questioned about sexual dysfunction and rating scales were not used to determine the level of sexual dysfunction at baseline, after initiation of SSRI therapy, and after initiation of mirtazapine therapy. However, once it was determined that the patients had sexual dysfunction, they were successfully treated with mirtazapine. Another concern could be that mirtazapine may have been added too early to the drug regimen. However, mirtazapine therapy was added after at least 6 to 8 weeks of SSRI therapy, which would have allowed for spontaneous reductions in sexual dysfunction. In most instances reported in the literature, the level of sexual dysfunction decreases by the end of the first 8 weeks of SSRI therapy.
1,2 However, this was not the case with my patients because sexual function had not improved over the first 8 weeks of their SSRI therapy. One patient discontinued mirtazapine therapy because of weight gain.
SSRI therapy is known to carry the risk of sexual dysfunction, [1] [2] [3] [4] and clinicians are often faced with the challenge of finding effective treatment strategies without compromising patient response to a particular agent. Controlled investigation is war- 3, 4 In addition, I recently had a patient who developed an obsessional image of a person's face that repeatedly appeared in his mind as he went about his activities. He did not know the person whose image he saw, and he became acutely distressed by the recurring appearance of this image. This patient had a diagnosis of schizophrenia with no past history of obsessive-compulsive symptoms and had been on treatment with risperidone, 4 mg/day, for 18 months. He was also receiving sodium valproate, 1000 mg/day; benzhexol, 4 mg/day; and a depot injection of zuclopenthixol, 400 mg every 2 weeks. The recurrent images disappeared after the dosage of risperidone was decreased to 3 mg/day.
It is likely that risperidone's potent serotonin (5-HT 2 ) antagonism has a role in the occurrence of obsessive-compulsive symptoms. Combinations of a serotonin reuptake inhibitor (SRI) and risperidone therefore would require close monitoring for a possible exacerbation of obsessive-compulsive symptoms.
Rathi Mahendran, M.Med.(Psych)
Singapore
Dr. Andrade Replies
Sir: Dr. Mahendran presents a case of obsessive imagery in a schizophrenic patient. She suggests that risperidone was responsible for the phenomena. Militating against her argument is the long duration (18 months) of uneventful use of risperidone. Favoring her argument is the disappearance of symptoms when the dose of risperidone was lowered. In the absence of mention of potentially dysequilibrating and re-equilibrating psychopharmacologic or psychosocial events, it is assumed that none existed. Rechallenge with risperidone was not attempted. Essentially, the etiologic role of risperidone in this case, while possible, remains unconfirmed.
Dr. Mahendran observes that I did not address risperidoneinduced obsessive-compulsive symptoms in my report; since the issue was peripheral to my subject, I had mentioned risperidone-induced worsening of such symptoms, but merely in passing. My report addressed a hazard of the risperidonefluoxetine combination; Dr. Mahendran describes a hazard of risperidone monotherapy.
Dr. Mahendran suggests that 5-HT 2 receptor antagonism with risperidone may underlie its propensity to induce or worsen obsessive-compulsive symptoms. Although most authors would agree, I believe that the mechanisms are far more complex. Consider the following: serotonin reuptake inhibitors (SRIs), in the long term, induce compensatory down-regulation of several presynaptic and postsynaptic serotonergic receptors, 1 whereas risperidone produces a direct, functional blockade of these receptors. 2 In addition, SRI drugs produce downstream dopaminergic inhibition, 3 whereas risperidone directly blocks dopamine receptors. 2 Such serotonergic and dopaminergic mechanisms may be therapeutically relevant in obsessive-compulsive disorder (OCD). 4, 5 These similarities of action suggest that risperidone may potentiate the action of SRI drugs in OCD. So, why would risperidone monotherapy or rapid dose escalation with risperidone precipitate or exacerbate obsessive-compulsive symptoms? The answer may lie in time-dependent changes: the described receptor actions of SRI drugs are delayed, whereas those of risperidone are immediate. Consequently, it is likely that SRI therapy primes the biological system in some hitherto unknown way, making later serotonergic and dopaminergic receptor changes therapeutic. Gradual dose escalation with risperidone, hypothetically, similarly allows the system to adapt. In contrast, risperidone monotherapy, rapid dose escalation, or high-dose treatment with risperidone overwhelms the receptors and does not allow the development of the putative compensatory therapeutic mechanisms.
This hypothesis explaining SRI-risperidone synergism has a homeopathic flavor. There is little better to offer, however, to explain the otherwise paradoxical observations that risperidone can both benefit as well as precipitate and/or worsen obsessivecompulsive symptoms, depending on the circumstances. In any case, Dr. Mahendran's concluding note is valid: that the SRI-risperidone combination requires close monitoring for possible exacerbation of obsessive-compulsive symptoms, a point which I, too, made in my report.
As a tailpiece: the patient described in my original letter 6 remained moderately to severely impaired 6 months after his initial exacerbation of obsessive-compulsive symptoms associated with risperidone use. After obtaining informed consent, he was rechallenged with risperidone (1 mg/day); his existing dosage of fluoxetine (60 mg/day) was continued unchanged. Amelioration of obsessive-compulsive symptomatology was observed. After 1 month, the dosage of risperidone was raised to 2 mg/day. There was rapid loss of the accrued gains. The dosage of risperidone was therefore lowered and maintained at 1 mg/day; this dosage was associated with acceptable response. These observations fit the argument that has been offered for the mechanism of risperidone-fluoxetine synergism. Further research with in vivo chemical challenges may, however, provide more information about the mechanisms involved. 14 that predispose them to the development or worsening of obsessive-compulsive symptoms during treatment with atypical antipsychotics, which are all strong antagonists at a variety of 5-HT receptors. 15 There have been reports of obsessivecompulsive symptoms improving or remaining unchanged in patients with Tourette's disorder 16, 17 and other OCD spectrum disorders 18 treated with risperidone, but no reports of obsessivecompulsive symptoms worsening in those patients. A second conclusion is that obsessive-compulsive symptoms most often occur with atypical antipsychotic monotherapy and improve with the addition of an SRI. 4, 7, 9, 10, 12 Third, obsessive-compulsive symptoms are seen much more commonly during treatment with higher doses of atypical antipsychotics (e.g., above
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